Fig. 1 · Structure

Documents & Downloads

BMS 599626 Hydrochloride (AC480 Hydrochloride)

Cat. No. A11209 CAS 873837-23-1

EGFR Inhibitor

BMS 599626 is an orally bioavailable inhibitor of the HER1, HER2 and HER4 tyrosine kinases (IC50=22, 32 and 190 nM, respectively) with potential antineoplastic activity.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

BMS 599626 Hydrochloride (AC480 Hydrochloride) Research Summary

This section summarizes 4 in vitro studies of BMS 599626 Hydrochloride (AC480 Hydrochloride) from 3 published references. In vitro models include membrane vesicles of insect cells containing ABCG2; K-1.

BMS 599626 Hydrochloride (AC480 Hydrochloride) In Vitro Studies

BMS 599626 inhibited vanadate-sensitive ABCG2 ATPase activity in insect-cell membrane vesicles in a concentration-dependent manner. In K-1 cells, treatment significantly lowered major signaling molecule levels in the EGFR/PI3K/AKT pathway compared with the negative control group. Treatment produced cell viability inhibition in A549 lung cancer cells. ABCG2 protein expression remained unchanged following treatment in resistant NCI-H460/MX20 cells. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Concentration-dependent inhibition of ABCG2 ATPase activity

Cell-based study · membrane vesicles of insect cells containing ABCG2 [1]

In membrane vesicles of insect cells containing ABCG2, BMS 599626 inhibited vanadate-sensitive ABCG2 ATPase activity in a concentration-dependent manner relative to basal activity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
vanadate-sensitive ATPase activity of ABCG2ATPase activity 0–40 µM final concentration: 7.6-fold inhibition of basal activity[1]

Literature-Reported Treatment Conditions

Treatment concentration
0–40 µM final concentration
Method
treated with BMS-599626
Reported limits
Not stated in the sentences used: schedule, vehicle.
Methods and source locations

Compound reported in the paper: BMS 599626

The paper names BMS 599626 without stating the salt or form; not verified as the hydrochloride form supplied as A11209. No dose conversion or lot validation.

2. Results > 2.8. BMS-599626 Inhibits the ATPase of ABCG2 (S37); 4. Materials and Methods > 4.8. ATPase Assay (S82)

vanadate-sensitive ATPase activity of ABCG2: vanadate-sensitive ATPase activity of ABCG2; comparator: basal activity — 2. Results > 2.8. BMS-599626 Inhibits the ATPase of ABCG2 (S37); 4. Materials and Methods > 4.8. ATPase Assay (S82)

Signaling protein levels in K-1 cells

Cell-based study · K-1 [2]

In K-1 cells, treatment at 10 µM significantly lowered the levels of major signaling molecules in the EGFR/PI3K/AKT pathway compared with the negative control group, as assessed by Western blot analysis.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Western blot analysis was used to detect the protein expression levels of EGFR, PI3K, p-PI3K, AKT, p-AKT and GALNT7Reported result the levels of major signaling molecules were significantly lower in the EGFR/PI3K/AKT pathway[2]

Literature-Reported Treatment Conditions

Treatment concentration
10 µM
Exposure duration
added after 24 h of cell culture; after 72 h of culture
Method
added
Vehicle
DMSO
Methods and source locations

Compound reported in the paper: BMS 599626

The paper names BMS 599626 without stating the salt or form; not verified as the hydrochloride form supplied as A11209. No dose conversion or lot validation.

Methods > Western blotting (S23, S24); Results > GALNT7 promotes cell proliferation and invasion by activating EGFR/PI3K/AKT pathway (S190, S191, S198)

Western blot analysis was used to detect the protein expression levels of EGFR, PI3K, p-PI3K, AKT, p-AKT and GALNT7: Western blot analysis was used to detect the protein expression levels of EGFR, PI3K, p-PI3K, AKT, p-AKT and GALNT7; comparator: negative control group — Results > GALNT7 promotes cell proliferation and invasion by activating EGFR/PI3K/AKT pathway (S191, S198)

Cell viability inhibition in lung cancer cells

Cell-based study · lung cancer cell line A549 [3]

In lung cancer A549 cells cultured in fresh medium, treatment inhibited cell viability after 48 h of incubation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
IC50 valuesReported result cell viability inhibition[3]

Literature-Reported Treatment Conditions

Exposure duration
48 h of incubation
Method
cultured in fresh medium
Vehicle
DMSO (final concentration, 0.1%)
Reported limits
Not stated in the sentences used: dose, control.
Methods and source locations

Compound reported in the paper: BMS 599626

The paper names BMS 599626 without stating the salt or form; not verified as the hydrochloride form supplied as A11209. No dose conversion or lot validation.

Methods > CCK8 assay to detect cell viability (S46, S47); Results > The suppression of the proliferation of human lung cancer cells by CEP-9722 and IMG (S150)

IC50 values: IC50 values — Results > The suppression of the proliferation of human lung cancer cells by CEP-9722 and IMG (S150)

ABCG2 protein expression in resistant cells

Cell-based study · NCI-H460/MX20 [1]

In resistant NCI-H460/MX20 cells, treatment at 300 nM for 72 h left ABCG2 protein expression unchanged.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
expression of ABCG2 proteinReported result the expression level of ABCG2 in the resistant NCI-H460/MX20 (Figure 6A,C) and HEK/ABCG2-R482 (Figure 6B,D) cells remained unchanged upon treatment with 300 nM BMS-599626 for 72 h.[1]

Literature-Reported Treatment Conditions

Treatment concentration
300 nM
Exposure duration
for 72 h
Method
treatment with 300 nM BMS-599626
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: BMS 599626

The paper names BMS 599626 without stating the salt or form; not verified as the hydrochloride form supplied as A11209. No dose conversion or lot validation.

2. Results > 2.7. BMS-599626 Does not Change the Total or Cell Membrane Expression of ABCG2 (S29); 4. Materials and Methods > 4.6. Immunoblotting (S76); Figure 6 legend (S113)

expression of ABCG2 protein: expression of ABCG2 protein; comparator: with or without BMS-599626 — 2. Results > 2.7. BMS-599626 Does not Change the Total or Cell Membrane Expression of ABCG2 (S29); Figure 6 legend (S113)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 873837-23-1
Applications EGFR Inhibitor
Formula C27H27FN8O3.HCl
Molecular Weight 567.1
Synonyms BMS-599626; AC-480; AC480 Hydrochloride
SMILES
CC1=C2C(=NC=NN2C=C1NC(=O)OC[C@@H]3COCCN3)NC4=CC5=C(C=C4)N(N=C5)CC6=CC(=CC=C6)F.Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 104 mg/mL (196.02 mM)
Water Insoluble
Ethanol 18 mg/mL (33.92 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
30% PEG400+0.5% Tween80+5% propylene glycol

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

BMS 599626 Hydrochloride (AC480 Hydrochloride) Research References

  1. [1] Ashar YV, Zhou J, Gupta P, et al. BMS-599626, a Highly Selective Pan-HER Kinase Inhibitor, Antagonizes ABCG2-Mediated Drug Resistance. Cancers (Basel) (2020). PMID: 32899268 DOI: 10.3390/cancers12092502 Source material
  2. [2] Wang Y, Wang C, Fu Z, et al. miR-30b-5p inhibits proliferation, invasion, and migration of papillary thyroid cancer by targeting GALNT7 via the EGFR/PI3K/AKT pathway. Cancer Cell Int (2021). PMID: 34819077 DOI: 10.1186/s12935-021-02323-x Source material
  3. [3] Cui X, Liu C, Dong P, et al. The combination therapy of isomucronulatol 7-O-beta-glucoside (IMG) and CEP-9722 targeting ferroptosis-related biomarkers in non-small cell lung cancer (NSCLC). BMC Pulm Med (2023). PMID: 37165402 DOI: 10.1186/s12890-023-02445-0 Source material

Added to your cart

View Cart Checkout
Loading...